person · Reporting owner
McDowell Caryn Gordon
Disclosed activity across 3 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CYTOKINETICS INCCYTK · Entity 3528 | GC & Chief Compliance Officer | February 27, 2018 | March 02, 2018 |
| Quince Therapeutics, Inc.CRTX · Entity 7403 | Chief Legal & Adm. Officer | June 06, 2022 | June 08, 2022 |
| Revance Therapeutics, Inc.RVNC · Entity 83521 | SVP, GC & Secretary | February 15, 2020 | February 19, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CYTOKINETICS INC
Report date February 27, 2018 · Filed March 02, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 35,000 |
Reported balance
After 2018-02-27 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2018-02-27 · Grant · Acquired 20,000 · Balance 35,000 F1: The restricted stock units vest in three annual installments. Vested shares will be delivered to the reporting person as follows: 40% on 02/27/2019, 40% on 02/27/2020 and 20% on 03/01/2021. |
| Common StockSEC Table I · non-derivative | Direct | 32,548 |
Reported balance
After 2018-02-28 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2018-02-28 · Tax withholding · Disposed 2,452 · Balance 32,548 |
| Incentive Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.80 · Expires 2028-02-27 | Direct | 15,226 |
Reported balance
After 2018-02-27 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-02-27 · Grant · Acquired 15,226 · Balance 15,226 F2: When the ISO and NQ dated 02/27/2018 are combined, the total grant shall vest and become exercisable in equal monthly installments such that the option shall be 100% vested on 02/27/2022. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.80 · Expires 2028-02-27 | Direct | 14,774 |
Reported balance
After 2018-02-27 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-02-27 · Grant · Acquired 14,774 · Balance 14,774 F2: When the ISO and NQ dated 02/27/2018 are combined, the total grant shall vest and become exercisable in equal monthly installments such that the option shall be 100% vested on 02/27/2022. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units vest in three annual installments. Vested shares will be delivered to the reporting person as follows: 40% on 02/27/2019, 40% on 02/27/2020 and 20% on 03/01/2021.
F2: When the ISO and NQ dated 02/27/2018 are combined, the total grant shall vest and become exercisable in equal monthly installments such that the option shall be 100% vested on 02/27/2022.
Quince Therapeutics, Inc.
Report date June 06, 2022 · Filed June 08, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 122,500 |
Ending reported balance
After 2022-06-06 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-06-06 · Tax withholding · Disposed 6,700 · Balance 133,300 F1: Represent shares sold to satisfy tax withholding obligations that arose in connection with the vesting of 17,500 shares of Restricted Stock Units granted on March 3, 2022. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 23, 2022. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.78 to $3.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Row 2 · 2022-06-06 · Sale · Disposed 10,800 · Balance 122,500 F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.78 to $3.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
Filing footnotes · ownership attribution and instrument terms
F1: Represent shares sold to satisfy tax withholding obligations that arose in connection with the vesting of 17,500 shares of Restricted Stock Units granted on March 3, 2022. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 23, 2022.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.78 to $3.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Revance Therapeutics, Inc.
Report date February 15, 2020 · Filed February 19, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 23,453 |
Reported balance
After 2020-02-15 transaction · row 1
1 source rowRow 1 · 2020-02-15 · Tax withholding · Disposed 864 · Balance 23,453 F1: Represents the number of shares withheld by and surrendered to the Issuer on February 15, 2020, to satisfy tax withholding obligations that arose in connection with the vesting of a Restricted Stock Award ("RSA") for 2,500 shares. The RSA vests in three equal annual installments from February 15, 2019, subject to Mrs. McDowell's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan (the "Plan")) on each vesting date. F2: The fair market value was determined on February 14, 2020 pursuant to the Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares withheld by and surrendered to the Issuer on February 15, 2020, to satisfy tax withholding obligations that arose in connection with the vesting of a Restricted Stock Award ("RSA") for 2,500 shares. The RSA vests in three equal annual installments from February 15, 2019, subject to Mrs. McDowell's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan (the "Plan")) on each vesting date.
F2: The fair market value was determined on February 14, 2020 pursuant to the Plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 06, 2017 Filed Oct 10, 2017 23:20 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 200 | $15.95 | $3,190.00 |
DisclosureSEC source: 0001061983-17-000060 · edgardoc.xml · nonDerivative · entry 21 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,369 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2017. Read SEC document |
| October 06, 2017 Filed Oct 10, 2017 23:20 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 200 | $15.75 | $3,150.00 |
DisclosureSEC source: 0001061983-17-000060 · edgardoc.xml · nonDerivative · entry 20 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,569 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2017. Read SEC document |
| October 06, 2017 Filed Oct 10, 2017 23:20 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 100 | $15.73 | $1,572.50 |
DisclosureSEC source: 0001061983-17-000060 · edgardoc.xml · nonDerivative · entry 19 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,769 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2017. Read SEC document |
| October 06, 2017 Filed Oct 10, 2017 23:20 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 1,100 | $15.70 | $17,270.00 |
DisclosureSEC source: 0001061983-17-000060 · edgardoc.xml · nonDerivative · entry 18 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,869 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2017. Read SEC document |
| October 06, 2017 Filed Oct 10, 2017 23:20 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 800 | $15.68 | $12,540.00 |
DisclosureSEC source: 0001061983-17-000060 · edgardoc.xml · nonDerivative · entry 17 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,969 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2017. Read SEC document |
| October 06, 2017 Filed Oct 10, 2017 23:20 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 700 | $15.65 | $10,955.00 |
DisclosureSEC source: 0001061983-17-000060 · edgardoc.xml · nonDerivative · entry 16 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,769 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2017. Read SEC document |
| October 06, 2017 Filed Oct 10, 2017 23:20 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 200 | $15.63 | $3,125.00 |
DisclosureSEC source: 0001061983-17-000060 · edgardoc.xml · nonDerivative · entry 15 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,469 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2017. Read SEC document |
| October 06, 2017 Filed Oct 10, 2017 23:20 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 1,100 | $15.60 | $17,160.00 |
DisclosureSEC source: 0001061983-17-000060 · edgardoc.xml · nonDerivative · entry 14 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,669 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2017. Read SEC document |
| October 06, 2017 Filed Oct 10, 2017 23:20 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 400 | $15.58 | $6,230.00 |
DisclosureSEC source: 0001061983-17-000060 · edgardoc.xml · nonDerivative · entry 13 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,769 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2017. Read SEC document |
| October 06, 2017 Filed Oct 10, 2017 23:20 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 700 | $15.55 | $10,885.00 |
DisclosureSEC source: 0001061983-17-000060 · edgardoc.xml · nonDerivative · entry 12 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,169 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2017. Read SEC document |
| October 06, 2017 Filed Oct 10, 2017 23:20 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 200 | $15.50 | $3,100.00 |
DisclosureSEC source: 0001061983-17-000060 · edgardoc.xml · nonDerivative · entry 11 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,869 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2017. Read SEC document |
| October 06, 2017 Filed Oct 10, 2017 23:20 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 600 | $15.40 | $9,240.00 |
DisclosureSEC source: 0001061983-17-000060 · edgardoc.xml · nonDerivative · entry 10 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,069 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2017. Read SEC document |
| October 06, 2017 Filed Oct 10, 2017 23:20 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 1,106 | $15.35 | $16,977.10 |
DisclosureSEC source: 0001061983-17-000060 · edgardoc.xml · nonDerivative · entry 9 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,669 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2017. Read SEC document |
| October 06, 2017 Filed Oct 10, 2017 23:20 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 200 | $15.33 | $3,065.00 |
DisclosureSEC source: 0001061983-17-000060 · edgardoc.xml · nonDerivative · entry 8 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,775 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2017. Read SEC document |
| October 06, 2017 Filed Oct 10, 2017 23:20 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 1,094 | $15.30 | $16,738.20 |
DisclosureSEC source: 0001061983-17-000060 · edgardoc.xml · nonDerivative · entry 7 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,975 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2017. Read SEC document |
| October 06, 2017 Filed Oct 10, 2017 23:20 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 383 | $15.28 | $5,850.33 |
DisclosureSEC source: 0001061983-17-000060 · edgardoc.xml · nonDerivative · entry 6 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,069 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2017. Read SEC document |
| October 06, 2017 Filed Oct 10, 2017 23:20 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 3,719 | $6.67 | $24,805.73 |
DisclosureSEC source: 0001061983-17-000060 · edgardoc.xml · nonDerivative · entry 5 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,452 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2017. Read SEC document |
| October 06, 2017 Filed Oct 10, 2017 23:20 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 500 | $15.25 | $7,625.00 |
DisclosureSEC source: 0001061983-17-000060 · edgardoc.xml · nonDerivative · entry 4 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,733 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2017. Read SEC document |
| October 06, 2017 Filed Oct 10, 2017 23:20 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 1,507 | $6.67 | $10,051.69 |
DisclosureSEC source: 0001061983-17-000060 · edgardoc.xml · nonDerivative · entry 3 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,233 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2017. Read SEC document |
| October 06, 2017 Filed Oct 10, 2017 23:20 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 2,000 | $15.20 | $30,400.00 |
DisclosureSEC source: 0001061983-17-000060 · edgardoc.xml · nonDerivative · entry 2 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,726 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2017. Read SEC document |
| October 06, 2017 Filed Oct 10, 2017 23:20 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 6,357 | $6.37 | $40,494.09 |
DisclosureSEC source: 0001061983-17-000060 · edgardoc.xml · nonDerivative · entry 1 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,726 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2017. Read SEC document |
| September 06, 2017 Filed Sep 8, 2017 20:48 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,432 | $0.00 Strike: $6.67 | $0.00 |
DisclosureSEC source: 0001061983-17-000057 · edgardoc.xml · derivative · entry 4 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,659 Underlying: Common Stock · 1,432 shares Expires 2026-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 06, 2017 Filed Sep 8, 2017 20:48 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 3,067 | $0.00 Strike: $6.67 | $0.00 |
DisclosureSEC source: 0001061983-17-000057 · edgardoc.xml · derivative · entry 3 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,715 Underlying: Common Stock · 3,067 shares Expires 2026-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 06, 2017 Filed Sep 8, 2017 20:48 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 5,732 | $0.00 Strike: $6.37 | $0.00 |
DisclosureSEC source: 0001061983-17-000057 · edgardoc.xml · derivative · entry 2 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,857 Underlying: Common Stock · 5,732 shares Expires 2025-05-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 06, 2017 Filed Sep 8, 2017 20:48 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 100 | $15.00 | $1,500.00 |
DisclosureSEC source: 0001061983-17-000057 · edgardoc.xml · nonDerivative · entry 1 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,369 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2017. Read SEC document |
| September 06, 2017 Filed Sep 8, 2017 20:48 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 707 | $14.95 | $10,569.65 |
DisclosureSEC source: 0001061983-17-000056 · edgardoc.xml · nonDerivative · entry 30 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,469 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2017. Read SEC document |
| September 06, 2017 Filed Sep 8, 2017 20:48 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 400 | $14.93 | $5,970.00 |
DisclosureSEC source: 0001061983-17-000056 · edgardoc.xml · nonDerivative · entry 29 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,176 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2017. Read SEC document |
| September 06, 2017 Filed Sep 8, 2017 20:48 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 600 | $14.90 | $8,940.00 |
DisclosureSEC source: 0001061983-17-000056 · edgardoc.xml · nonDerivative · entry 28 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,576 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2017. Read SEC document |
| September 06, 2017 Filed Sep 8, 2017 20:48 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 724 | $14.85 | $10,751.40 |
DisclosureSEC source: 0001061983-17-000056 · edgardoc.xml · nonDerivative · entry 27 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,176 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2017. Read SEC document |
| September 06, 2017 Filed Sep 8, 2017 20:48 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 100 | $14.83 | $1,482.50 |
DisclosureSEC source: 0001061983-17-000056 · edgardoc.xml · nonDerivative · entry 26 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,900 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2017. Read SEC document |
| September 06, 2017 Filed Sep 8, 2017 20:48 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 400 | $14.80 | $5,920.00 |
DisclosureSEC source: 0001061983-17-000056 · edgardoc.xml · nonDerivative · entry 25 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2017. Read SEC document |
| September 06, 2017 Filed Sep 8, 2017 20:48 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 400 | $14.78 | $5,910.00 |
DisclosureSEC source: 0001061983-17-000056 · edgardoc.xml · nonDerivative · entry 24 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,400 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2017. Read SEC document |
| September 06, 2017 Filed Sep 8, 2017 20:48 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 600 | $14.75 | $8,850.00 |
DisclosureSEC source: 0001061983-17-000056 · edgardoc.xml · nonDerivative · entry 23 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,800 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2017. Read SEC document |
| September 06, 2017 Filed Sep 8, 2017 20:48 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 200 | $14.73 | $2,945.00 |
DisclosureSEC source: 0001061983-17-000056 · edgardoc.xml · nonDerivative · entry 22 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,400 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2017. Read SEC document |
| September 06, 2017 Filed Sep 8, 2017 20:48 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 500 | $14.70 | $7,350.00 |
DisclosureSEC source: 0001061983-17-000056 · edgardoc.xml · nonDerivative · entry 21 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,600 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2017. Read SEC document |
| September 06, 2017 Filed Sep 8, 2017 20:48 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 200 | $14.65 | $2,930.00 |
DisclosureSEC source: 0001061983-17-000056 · edgardoc.xml · nonDerivative · entry 20 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,100 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2017. Read SEC document |
| September 06, 2017 Filed Sep 8, 2017 20:48 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 300 | $14.63 | $4,387.50 |
DisclosureSEC source: 0001061983-17-000056 · edgardoc.xml · nonDerivative · entry 19 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,300 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2017. Read SEC document |
| September 06, 2017 Filed Sep 8, 2017 20:48 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 700 | $14.60 | $10,220.00 |
DisclosureSEC source: 0001061983-17-000056 · edgardoc.xml · nonDerivative · entry 18 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,600 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2017. Read SEC document |
| September 06, 2017 Filed Sep 8, 2017 20:48 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 200 | $14.58 | $2,915.00 |
DisclosureSEC source: 0001061983-17-000056 · edgardoc.xml · nonDerivative · entry 17 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,300 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2017. Read SEC document |
| September 06, 2017 Filed Sep 8, 2017 20:48 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 200 | $14.53 | $2,905.00 |
DisclosureSEC source: 0001061983-17-000056 · edgardoc.xml · nonDerivative · entry 16 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,500 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2017. Read SEC document |
| September 06, 2017 Filed Sep 8, 2017 20:48 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 200 | $14.50 | $2,900.00 |
DisclosureSEC source: 0001061983-17-000056 · edgardoc.xml · nonDerivative · entry 15 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,700 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2017. Read SEC document |
| September 06, 2017 Filed Sep 8, 2017 20:48 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 200 | $14.48 | $2,895.00 |
DisclosureSEC source: 0001061983-17-000056 · edgardoc.xml · nonDerivative · entry 14 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,900 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2017. Read SEC document |
| September 06, 2017 Filed Sep 8, 2017 20:48 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 600 | $14.45 | $8,670.00 |
DisclosureSEC source: 0001061983-17-000056 · edgardoc.xml · nonDerivative · entry 13 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,100 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2017. Read SEC document |
| September 06, 2017 Filed Sep 8, 2017 20:48 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 400 | $14.40 | $5,760.00 |
DisclosureSEC source: 0001061983-17-000056 · edgardoc.xml · nonDerivative · entry 12 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,700 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2017. Read SEC document |
| September 06, 2017 Filed Sep 8, 2017 20:48 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 200 | $14.38 | $2,875.00 |
DisclosureSEC source: 0001061983-17-000056 · edgardoc.xml · nonDerivative · entry 11 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,100 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2017. Read SEC document |
| September 06, 2017 Filed Sep 8, 2017 20:48 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 200 | $14.35 | $2,870.00 |
DisclosureSEC source: 0001061983-17-000056 · edgardoc.xml · nonDerivative · entry 10 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,300 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2017. Read SEC document |
| September 06, 2017 Filed Sep 8, 2017 20:48 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 302 | $14.30 | $4,318.60 |
DisclosureSEC source: 0001061983-17-000056 · edgardoc.xml · nonDerivative · entry 9 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,500 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2017. Read SEC document |
| September 06, 2017 Filed Sep 8, 2017 20:48 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 100 | $14.28 | $1,427.50 |
DisclosureSEC source: 0001061983-17-000056 · edgardoc.xml · nonDerivative · entry 8 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,802 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2017. Read SEC document |
| September 06, 2017 Filed Sep 8, 2017 20:48 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 400 | $14.25 | $5,700.00 |
DisclosureSEC source: 0001061983-17-000056 · edgardoc.xml · nonDerivative · entry 7 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,902 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2017. Read SEC document |
| September 06, 2017 Filed Sep 8, 2017 20:48 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 898 | $14.20 | $12,751.60 |
DisclosureSEC source: 0001061983-17-000056 · edgardoc.xml · nonDerivative · entry 6 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,302 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.